Pharmacol Rep 66:169173 Dungan KM, Povedano ST, Forst T, Gonzlez JGG, Atisso C, Sealls W, Fahrbach JL (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Recognizing these exclusive benefits can guide individuals and medical practitioners toward selecting a suitable peptide that targets particular therapeutic goals or health-related circumstances
Proc Natl Acad Sci USA 92 : 10281032 Girnita A, Girnita L, Prete Fd F, Bartolazzi A, Larsson O, Axelson M (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
For orforglipron, participants initiated on higher doses and those on rapid titration schemes appeared to have higher discontinuation rates, providing insights into the optimisation process for the phase 3 trials